Discovery of novel 4-aryl-thieno[1,4] diazepin-2-one derivatives targeting multiple protein kinases as anticancer agents
- Authors
- Lee, Junghun; Jung, Hoyong; Kim, Minjung; Lee, Eunkyu; Im, Daseul; Aman, Waqar; Hah, Jung-Mi
- Issue Date
- May-2018
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- 4-Aryl-thieno[1,4] diazepin-2-one; Antiproliferative activity; Hematopoietic cell line; Kinase inhibitor; Multiple protein kinase inhibitor
- Citation
- BIOORGANIC & MEDICINAL CHEMISTRY, v.26, no.8, pp 1628 - 1637
- Pages
- 10
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- BIOORGANIC & MEDICINAL CHEMISTRY
- Volume
- 26
- Number
- 8
- Start Page
- 1628
- End Page
- 1637
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/6236
- DOI
- 10.1016/j.bmc.2018.02.009
- ISSN
- 0968-0896
1464-3391
- Abstract
- A series of 4-aryl-thieno[1,4] diazepin-2-one were synthesized and evaluated for their antiproliferative activities against the A375P melanoma and U937 hematopoietic cell lines. Several compounds showed very potent antiproliferative activities toward both cell lines and the activities were better than that of sorafenib, the reference standard. Derivatives were made as amide (8a-8i, 9a-9m) and urea (10a-10d, 11a-11d) with diverse hydrophobic moieties. One of the most potent inhibitor 10d, 1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin4-yl)phenyl) urea was found to be very potent inhibitor of multi-protein kinases including FMS kinase (IC50 = 3.73 nM) and is a promising candidate for further development in therapeutics for cancer. (c) 2018 Elsevier Ltd. All rights reserved.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.